Publication Name	World Journal of Clinical Oncology
Manuscript ID	21856
Country	France

Received	2015-07-30 09:10
Peer-Review Started	2015-07-31 09:39
To Make the First Decision	2015-09-16 09:00
Return for Revision	2015-09-28 09:52
Revised
Second Decision	2016-03-28 08:49
Accepted by Journal Editor-in-Chief	2016-03-30 18:45
Accepted by Company Editor-in-Chief	2016-04-11 11:42
Articles in Press	2016-04-11 17:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-05-16 19:40
Publish the Manuscript Online	2016-06-03 09:36

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Neoadjuvant therapy for gastroesophageal adenocarcinoma
Manuscript Source	Invited Manuscript
All Author List	Emmanuelle Samalin and Marc Ychou
Funding Agency and Grant Number
Corresponding Author	Emmanuelle Samalin, MD, Digestive Oncology Department, Institut régional du Cancer de Montpellier (ICM), 208 avenue des Apothicaires, 34298 Montpellier, France. emmanuelle.samalin@icm.unicancer.fr
Key Words	Gastric adenocarcinoma; Lower esophagus adenocarcinoma; Gastroesophageal junction adenocar­cinoma; Preoperative treatment; Neoadjuvant treatment
Core Tip	Gastric and esophageal adenocarcinomas are one of the main causes of cancer-related death worldwide. The incidence of gastroesophageal junc-tion adenocarcinoma is rapidly rising in Western countries. Surgical resection is currently the major cura-tive treatment. As the 5-year survival rate highly depends on the pTNM stage, the treatment strategy is very challenging for oncologists. Several treatments, including systemic chemotherapy, are being assessed to prevent recurrences and improve overall survival. New strategies, such as induction chemotherapy followed by preoperative chemoradiotherapy, targeted therapies and new cytotoxic regimens in perioperative chemotherapy, are currently assessed to improve current standards and develop more tailored therapeutic interventions.
Publish Date	2016-06-03 09:36
Citation	Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016; 7(3): 284-292
URL	http://www.wjgnet.com/2218-4333/full/v7/i3/284.htm
DOI	http://dx.doi.org/10.5306/wjco.v7.i3.284

Full Article (PDF)	WJCO-7-284.pdf
Full Article (Word)	WJCO-7-284.doc
Manuscript File	21856-Review.docx
Answering Reviewers	21856-Answering reviewers.pdf
Audio Core Tip	21856-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	21856-Conflict-of-interest statement.pdf
Copyright License Agreement	21856-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	21856-Language certificate.pdf
Peer-review Report	21856-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	21856-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	21856-Scientific misconduct check.pdf
Scientific Editor Work List	21856-Scientific editor work list.pdf